News
CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...
3h
Dealbreaker on MSNGilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition
Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...
On Friday, the U.S. District Court for the District of Maryland paused several parts of a health insurance exchange enrollment and eligibility rule that was set to take effect today. The court agreed ...
Fort Worth’s oldest African American Baptist church, which was recently put on a list of Most Endangered Places in the city, ...
Republicans aren’t known for raising hell about prescription drug prices and fighting to keep them as low as possible for ...
Here are the nominees for the Marion Star Football Player of Week 1 Poll that runs through early Tuesday morning.
The Handmaid's Tale is full of ostensibly harmless-sounding catchphrases whose entire meaning only reveals itself when read ...
Triad’s football team suffered a home-opening loss to Mount Gilead by a 31-6 count on Friday to kick off the 2025 season. The ...
It was a new season, but Jonathan Alder’s football squad made a big statement. The Pioneers started the year on the road at ...
3d
TipRanks on MSNGilead Sciences Advances Lung Cancer Treatment with New Clinical Study
Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results